

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on August 23, 2007.

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1645

Patent Application

Docket No. ARS-121

Serial No. 10/566,929

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645  
Applicant : Meija Yang  
Serial No. : 10/566,929  
Filed : February 2, 2006  
Conf. No. : 1147  
For : Novel Therapeutic Fusion Proteins

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Frank C. Eisenschenk". The signature is fluid and cursive, with the first name "Frank" being more legible than the last name "Eisenschenk".

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of cited references

Substitute for form 1449B/PTO

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/566,929
Filing Date	February 2, 2006
First Named Inventor	Meija Yang
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ARS-121

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BHATT, L. <i>et al.</i> "The Hereditary Hemochromatosis Protein HFE and Its Chaperone $\beta$ 2-microglobulin Localise Predominantly to the Endosomal-Recycling Compartment", <i>Biochem Biophys Res Commun</i> , 2007, pp. 277-284, Vol. 359.	
	R2	GROMMÉ, M. <i>et al.</i> "Recycling MHC Class I Molecules and Endosomal Peptide Loading", <i>Proc Natl Acad Sci USA</i> , August 1999, pp. 10326-10331, Vol. 96.	
	R3	LEBRÓN, J. A. <i>et al.</i> "The Hemochromatosis Protein HFE Competes with Transferrin for Binding to Transferrin Receptor", <i>J Mol Biol</i> , 1999, pp. 239-245, Vol. 294.	
	R4	WAHEED, A. <i>et al.</i> "Hereditary Hemochromatosis: Effects of C282Y and H63D Mutations on Association With $\beta$ 2-Microglobulin, Intracellular Processing, and Cell Surface Expression of the HFE Protein in COS-7 Cells", <i>Proc Natl Acad Sci USA</i> , November 1997, pp. 12384-12389, Vol. 94.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.